Brokerages Set Neumora Therapeutics, Inc. (NASDAQ:NMRA) PT at $6.57

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) have received a consensus rating of “Moderate Buy” from the ten research firms that are covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation, one has given a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $6.5714.

A number of equities analysts recently commented on the stock. Needham & Company LLC reduced their price objective on shares of Neumora Therapeutics from $8.00 to $5.00 and set a “buy” rating for the company in a research note on Tuesday, June 16th. Mizuho dropped their target price on Neumora Therapeutics from $6.00 to $4.00 and set an “outperform” rating on the stock in a research report on Thursday, June 18th. Weiss Ratings downgraded Neumora Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 14th. HC Wainwright reissued a “buy” rating on shares of Neumora Therapeutics in a research report on Tuesday, July 28th. Finally, Royal Bank Of Canada reduced their price target on Neumora Therapeutics from $7.00 to $5.00 and set an “outperform” rating for the company in a research report on Monday, July 13th.

Insider Transactions at Neumora Therapeutics

In other Neumora Therapeutics news, insider Daljit Singh Aurora sold 91,690 shares of the business’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $1.50, for a total value of $137,535.00. Following the completion of the transaction, the insider directly owned 48,750 shares in the company, valued at approximately $73,125. The trade was a 65.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders sold a total of 453,833 shares of company stock valued at $701,219 in the last 90 days. 26.94% of the stock is owned by insiders.

Institutional Trading of Neumora Therapeutics

A number of institutional investors have recently modified their holdings of NMRA. HBK Sorce Advisory LLC bought a new position in shares of Neumora Therapeutics during the 2nd quarter worth approximately $26,000. Hsbc Holdings PLC acquired a new stake in Neumora Therapeutics in the fourth quarter valued at approximately $27,000. Virtu Financial LLC purchased a new position in Neumora Therapeutics in the third quarter worth $31,000. Fred Alger Management LLC purchased a new position in Neumora Therapeutics in the fourth quarter worth $40,000. Finally, Canada Pension Plan Investment Board acquired a new position in shares of Neumora Therapeutics during the second quarter worth $41,000. 47.65% of the stock is currently owned by institutional investors.

Neumora Therapeutics Trading Down 4.3%

NASDAQ NMRA opened at $1.33 on Tuesday. The company has a debt-to-equity ratio of 1.19, a quick ratio of 4.50 and a current ratio of 4.50. The company has a market capitalization of $249.91 million, a price-to-earnings ratio of -1.08 and a beta of 2.75. The company’s 50-day simple moving average is $1.61 and its two-hundred day simple moving average is $2.07. Neumora Therapeutics has a one year low of $0.83 and a one year high of $3.65.

Neumora Therapeutics (NASDAQ:NMRA) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.01. Equities analysts forecast that Neumora Therapeutics will post -0.85 EPS for the current fiscal year.

About Neumora Therapeutics

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.